BIOMAT Database Logo BIOMAT Database Logo

Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle. 1996

L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Département d'Hématologie, hôpital Pitié-Salpétrière Paris, France.

We report on 71 consecutive patients with de novo myelodysplastic syndromes referred to physicians belonging to the Société française de greffe de moelle from 1982 through 1991 and transplanted with marrow from HLA-identical siblings. There were 16 cases of refractory anemia, 27 of refractory anemia with excess of blast cells, and 28 of refractory anemia with excess of blast cells in transformation. Seventeen patients had received cytoreductive chemotherapy before the graft. The disease progressed in 17 patients between diagnosis and grafting. Twenty-three patients are alive with a median follow-up of 6 years, whereas 24 died from relapse and 24 from transplant-related complications. Kaplan-Meier estimates of event-free survival, relapse and transplant-related mortality at 7 years were 32%, 48%, and 39%, respectively. The log-rank test and Cox's model revealed better outcome among young patients, patients in an early stage of the French-American-British (FAB) classification or with a low percentage of marrow blasts before transplantation, patients who did not undergo cytoreductive chemotherapy before transplantation, and patients conditioned with total body irradiation and cyclophosphamide. The high rate of relapse in advanced FAB stages has led us to graft patients earlier in the course of the disease, and we are currently conducting a multicenter, randomized study to determine the value of intensive chemotherapy before grafting in patients with an excess of marrow blasts.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
May 1997, Bone marrow transplantation,
L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
December 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
November 2003, Bone marrow transplantation,
L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
September 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
October 1995, Bone marrow transplantation,
L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).
December 2000, Bone marrow transplantation,
L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
June 1995, Bone marrow transplantation,
L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.
February 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM).
June 1997, British journal of haematology,
L Sutton, and C Chastang, and P Ribaud, and J P Jouet, and M Kuentz, and M Attal, and J Reiffers, and J M Tigaud, and B Rio, and C Dauriac, and M Legros, and F Dreyfus, and B Lioure, and X Troussard, and N Milpied, and F Witz, and P Oriol, and J Y Cahn, and M Michallet, and E Gluckman, and N Ifrah, and J L Pico, and E Vilmer, and V Leblond
Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM).
February 2000, British journal of haematology,
Copied contents to your clipboard!